Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

In the recent news, Viking Therapeutics, on Jan. 8, announced the initiation of Phase 2 VENTURE-oral dosing trial of VK2735 tablet formulation in patients with obesity. “This group is just not ...

This is despite VKTX VK2735 subcutaneous therapy already triggering the "significant reductions in mean body weight from baseline, ranging up to -14.7%, as well as statistically significant ...

Now let's talk about the new kid in town. Viking focuses on GIP/GLP-1 receptor agonists and has a candidate, VK2735, in late-stage clinical trials. As an injectable (like the Novo Nordisk and ...

Viking (VKTX) is in the midst of a phase 2a dosing trial of its oral obesity drug VK2735, with a data readout expected in the second half of the year. The company is expected to launch a phase 3 ...

The real Holy Grail is a weight-loss-in-a-pill formulation, which has investors very interested in Viking Therapeutics‘ (NASDAQ:VKTX) VK2735, which is showing better efficacy than Novo Nordisk ...

When you first enter a new world, you can either spawn near a structure or find one while exploring any of the three dimensions. While finding some can be quite easy, others are extremely hard to ...

In contrast, Viking Therapeutics' shares experienced modest gains. Viking's VK2735, a dual GLP-1/GIP receptor agonist, is seen as potentially superior to Novo Nordisk's semaglutide, which only targets ...

Sure, the Viking bulls could point out that there’s more than just VK2735 in its pipeline, with exposure in NASH and X-ALD. However, all of these developments are pre-stage III, and thus ...